IRIS
VELLA, VERONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.229
EU - Europa 1.022
AS - Asia 176
OC - Oceania 3
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.433
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.183
IE - Irlanda 320
UA - Ucraina 282
GB - Regno Unito 111
CN - Cina 99
DE - Germania 79
IT - Italia 53
SE - Svezia 51
CA - Canada 46
IN - India 44
FI - Finlandia 43
CH - Svizzera 42
BE - Belgio 16
IL - Israele 10
TR - Turchia 9
ES - Italia 7
EE - Estonia 6
HK - Hong Kong 6
IR - Iran 6
FR - Francia 4
AU - Australia 2
NG - Nigeria 2
NL - Olanda 2
BG - Bulgaria 1
BN - Brunei Darussalam 1
EU - Europa 1
IS - Islanda 1
LI - Liechtenstein 1
NZ - Nuova Zelanda 1
OM - Oman 1
PL - Polonia 1
PT - Portogallo 1
RO - Romania 1
Totale 2.433
Salva come PNG Salva come JPEG
Città #
Dublin 320
Chandler 263
Jacksonville 252
London 102
Wilmington 68
Beijing 48
Dearborn 46
Chicago 44
Helsinki 43
Toronto 42
Zurich 42
Boardman 36
San Mateo 29
Capo D'orlando 27
Princeton 27
Ann Arbor 19
Ashburn 17
Brussels 16
Falls Church 16
Leawood 16
Padova 12
Azor 10
New Orleans 10
Augusta 9
Hefei 9
Norwalk 9
Edinburgh 8
Kunming 8
Monmouth Junction 8
Istanbul 7
Madrid 7
Hong Kong 6
Milan 6
Tallinn 6
Pune 5
Nanchang 4
Ardabil 3
Bangalore 3
Des Moines 3
Gunzenhausen 3
Jaipur 3
Nanjing 3
Wuhan 3
Atlanta 2
Cambridge 2
Falkenstein 2
Frankfurt am Main 2
Guangzhou 2
Hangzhou 2
Jinan 2
Kocaeli 2
Lagos 2
Montreal 2
Mumbai 2
Seattle 2
Shenyang 2
Sydney 2
Amsterdam 1
Auckland 1
Bandar Seri Begawan 1
Borås 1
Bremen 1
Bucharest 1
Catania 1
Changsha 1
Chongqing 1
Fuzhou 1
Henderson 1
Houston 1
Jinhua 1
Lanzhou 1
Lisbon 1
New York 1
Ningbo 1
Paris 1
Reykjavik 1
Salalah 1
Shaoxing 1
Sofia 1
Staten Island 1
Vaduz 1
Warsaw 1
Yinchuan 1
Zhengzhou 1
Totale 1.673
Salva come PNG Salva come JPEG
Nome #
The p53-homologue p63may promote thyroid cancer progression 114
TAp63α antagonizes p53 oncosuppressor function in thyroid cancer cells 112
TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation 102
p53 family proteins in thyroid cancer 99
p73 Tumor-Suppressor Activity is Impaired in Human thyroid Cancer 95
BRAF(V600E) mutation and the biology of papillary thyroid cancer 64
Metabolic alterations of thyroid cancer as potential therapeutic targets 64
P73 tumor-suppressor activity is impaired in human thyroid cancer 63
Novel cross-talk between IGF-IR and DDR1 regulates IGF-IR trafficking, signaling and biological responses 60
The IGF system in thyroid cancer:new concepts 57
Insulin Receptor Isoforms and Insulin-Like Growth Factor Receptor in Human Follicular Cell Precursors from Papillary Thyroid Cancer and Normal Thyroid 57
Insulin Resistance: Any Role in the Changing Epidemiology of Thyroid Cancer? 57
Anaplastic Thyroid Cancer in Sicily: The Role of Environmental Characteristics 56
Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer 54
Immunostaining for MET/HCF receptor may be useful to identify malignancies in thyroid lesions classified suspicious at fine-needle aspiration biopsy 54
DeltaNp73alpha inhibits PTEN expression in thyroid cancer cells 54
Exclusion of c-Abl from the Nucleus Restrains the p73 Tumor Suppression Function 53
IGF-I induces upregulation of DDR1 collagen receptor in breast cancer cells by suppressing MIR-199a-5p through the PI3K/AKT pathway 52
Interleukin-4 stimulates papillary thyroid cancer cell survival: implications in patients with thyroid cancer and concomitant Graves' disease 51
TAp73 Increases tumor suppressor activity in thyroid cancer cells via the inhibition of mdm2-mediated degradation 51
Levels of histone acetylation in thyroid tumors. 48
Discoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells 48
Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor 47
Thyrospheres From Normal or Malignant Thyroid Tissue Have Different Biological, Functional, and Genetic Features 47
Reactivation of p53 mutants by p53 reactivation and induction of massive apoptosis in thyroid cancer cells 45
PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis 44
A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer 39
Thyrospheres: a new in vitro model for testing human thyroid endocrine disruptors 38
Recent views of heavy metals as possible risk factors and potential preventive and therapeutic agents in prostate cancer 38
Insulin Receptor Isoforms in Physiology and Disease: An Updated View 38
null 33
Il BRAF(V600E) è responsabile della resistenza delle cellule di carcinoma tiroideo al Gefitinib 33
null 29
null 29
null 27
The expression of PTEN tumor suppressor is down regulated by dominant negative p73 isoform ΔNp73 in thyroid cancer cells 27
null 26
null 25
null 25
null 25
null 25
Identification of Thyroid Cancer Stem Cells 25
miRNA upregulation in thyroid cancer is caused by the inhibition of the p53 pathway 25
null 24
null 24
null 23
null 22
null 22
null 21
Effetto del trattamento epigenetico combinato di acido valproico e 5-Azacitidina in un modello di carcinomi della Tiroide poco differenziati 21
Isolation of thyroid cancer stem cells 21
Regulation of miRNAs by p53 family members in thyroid cancer cells 21
Genome wide analysis in papillary thyroid carcinoma 19
Reactivation of p53 mutants by small compounds may represent an adjuvant therapy of poorly differentiated thyroid cancer 19
Thyrospheres an in vitro model for human thyroid carcinogenesis 19
In IGF-IR deficient leiomyosarcoma cells IGF-II stimulates biological effects via the insulin receptor isoform A 18
Role of Braf (v600) mutation in the resistance to Gefitinib of thyroid cancer cells. 16
Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway. 7
Insulin/IGF axis and the Receptor for Advanced Glycation End Products: role in meta-inflammation and potential in cancer therapy 5
RAGE inhibition blunts insulin-induced oncogenic signals in breast cancer 5
COVID-19 and Diabetes: The Importance of Controlling RAGE 5
Activation of the s100a7/rage pathway by igf-1 contributes to angiogenesis in breast cancer 5
Metformin counteracts stimulatory effects induced by insulin in primary breast cancer cells 3
Triple-negative breast cancer drug resistance, durable efficacy, and cure: how advanced biological insights and emerging drug modalities could transform progress 3
Microenvironmental Determinants of Breast Cancer Metastasis: Focus on the Crucial Interplay Between Estrogen and Insulin/Insulin-Like Growth Factor Signaling 1
IGF2: A Role in Metastasis and Tumor Evasion from Immune Surveillance? 1
Ddr1 affects metabolic reprogramming in breast cancer cells by cross-talking to the insulin/igf system 1
Editorial: Early diagnoses and treatments of uncommon breast cancers 1
IFN-I signaling in cancer: the connection with dysregulated Insulin/IGF axis 1
Totale 2.483
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.659
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.659
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201942 0 0 0 0 0 0 0 0 0 0 0 42
2019/2020354 0 42 0 42 27 61 48 60 18 9 47 0
2020/2021487 45 0 42 42 0 43 0 108 44 44 76 43
2021/2022267 0 0 4 69 9 25 3 59 21 27 15 35
2022/2023854 62 19 29 121 128 108 14 104 122 26 99 22
2023/2024443 40 76 46 27 71 24 86 26 23 24 0 0
Totale 2.483